2Sehn LH,Berry B,Chhanabhai M,et al.The revised International Prog- nostic Index(R-IPI)is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-GHOP[J].Blood,2007,109(5):1857-1861.
4Hans CP,Weisenburger DD,Greiner TC,et al.Confirmation of the mo- lecular classification of diffuse large B-cell lymphoma by immunohisto- chemistry using a tissue microarray[J].Blood,2004,103(1):275-282.
5Choi WW,Weisenburger DD,Greiner TC,et al.A new immunostain al- gorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy[J].Clin Cancer Res,2009,15(17):5494-5502.
6Barrans S,Crouch S,Smith A,et al.Rearrangement of MYC is associat- ed with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab[J].J CIin OncoI,2010,28(20):3360-3365.
8Savage KJ,Johnson NA,Ben-Neriah S,et al.MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with H-CHOP chemotherapy[J].Blood,2009,114(17);3533-3537.
9Chen Y,Dave BJ,Zhu X,et al.Differences in the cytogenetic alteration profiles of diffuse large B-cell lymphoma among Chinese and American patients[J].Cancer Genet,2013,206(5):183-190.
10Gascoyne RD,Adomat SA,Krajewski S,et al.Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma[J].Blood,1997,90(1):244-251.
